2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994




    

Company Abstracts  ::  2003

2003 Presentation Abstracts
 

2003 Publications Abstracts


RENAL FLARE IN SLE PATIENTS WITH IMPAIRED RENAL FUNCTION IN A RCT OF LJP 394
James A Tumlin, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology
San Diego, CA
November 12-17, 2003

SAFETY RESULTS FROM A RCT OF LJP 394 IN SLE PATIENTS WITH A HISTORY OF RENAL DISEASE
Daniel J Wallace, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology

San Diego, CA
November 12-17, 2003


EFFICACY RESULTS FROM A RCT OF LJP 394 IN SLE PATIENTS WITH HISTORY OF RENAL DISEASE
James A Tumlin, MD, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology
San Diego, CA
November 12-17, 2003


REDUCTIONS IN ANTI-DSDNA ANTIBODIES AND REDUCED RISK OF SLE RENAL FLARE AND MAJOR SLE FLARE
Matthew D Linnik, et al.
Presented at the
36th Annual Meeting of the American Society of Nephrology

San Diego, CA
November 12-17, 2003


DOMAIN SPECIFICITY OF AUTOANTIBODIES TO BETA2-GLYCOPROTEIN I IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME ENROLLED IN A PHASE 1/2 TRIAL WITH LJP 1082
Matthew D. Linnik, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003


CLINICAL EFFICACY RESULTS FROM A RCT OF LJP 394 IN SLE PATIENTS WITH HISTORY OF RENAL DISEASE
Mario H Cardiel, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology

Orlando, FL
October 23-28, 2003


SAFETY RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (RCT) OF LJP 394 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH A HISTORY OF RENAL DISEASE
Daniel J Wallace, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003


SLE PATIENTS WITH SUSTAINED REDUCTIONS IN ANTI-DSDNA ANTIBODIES HAVE A REDUCED RISK OF RENAL FLARE AND MAJOR SLE FLARE
Matthew D Linnik, et al.
Presented at the
67th Annual Meeting of the
American College of Rheumatology
Orlando, FL
October 23-28, 2003


RESULTS OF A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PHASE 1/2 CLINICAL TRIAL (RCT) TO ASSESS THE SAFETY AND TOLERABILITY OF LJP 1082 IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
Arash Horizon, et al.
Presented at the
67th Annual Meeting of the American College of Rheumatology
Orlando, FL
October 23-28, 2003


SMALL MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY AND AUTOIMMUNE DISORDERS
Luisa Salter-Cid, et al
Presented at
Inflammatory Processes in Drug Discovery
Philadelphia, PA
September 22-23, 2003


RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND PHASE III CLINICAL TRIAL FOR THE EVALUATION OF LJP 394 (ABETIMUS SODIUM) IN THE TREATMENT OF PATIENTS WITH SLE WHO ARE AT RISK FOR RENAL FLARE
Mario Cardiel for the LJP 394-90-09 Study Investigators Group
Presented at the
Annual European Congress of Rheumatology "EULAR 2003"

Lisbon, Portugal
June 18-21, 2003


 


IN VIVO CHARACTERIZATION OF BIOCONJUGATE B CELL TOLERAGENS WITH SPECIFICITY FOR AUTOANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME
Cockerill KA, et al.

Published in
International Immunopharmacology, 2003
Volume 3, Issue 12: pp 1667-1675


LJP 394 FOR THE PREVENTION OF RENAL FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Donato Alarcón-Segovia, et al.
Published in
Arthritis and Rheumatism, 2003

Volume 48, Issue 2: pp 442-454



IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ENROLLED IN A RANDOMIZED CLINICAL TRIAL COMPARING LJP 394 TREATMENT WITH PLACEBO
V. Strand, et al.
Published in
Lupus 2003
Volume 12: pp. 677-686


MULTIVALENT POLY(ETHYLENE GLYCOL)-CONTAINING CONJUGATES FOR IN VIVO ANTIBODY SUPPRESSION
Dave Jones, et al
Published in
Bioconjugate Chemistry, 2003
Volume 14, Issue 6: 1067-1076





Terms of Use & Privacy Policy
Copyright © 2007, La Jolla Pharmaceutical Company